89bio Inc. (ETNB)
NASDAQ (NMS) NASDAQ (NMS) Primary 
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Well, welcome, everyone, and it's really a privilege for me to introduce our next participating company at the Cantor Global Healthcare Conference. First time Steve Seedhouse from the biotech team.
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director So welcome to the next session of the Citi Biopharma back-to-school event. So my name is Geoff Meacham.
89bio: Promising As Pegozafermin Nears Phase 3 Readout
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better safety profile compared to competitors, potentially capturing significant market share in MASH and SHTG. Financially, 89bio has a solid cash position but may need to raise capital by mid to late 2026, posing dilution risk.
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Should You Buy 89BIO (ETNB) After Golden Cross?
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
89bio's Pegozafermin Is Now Gaining Momentum
89bio's Pegozafermin Is Now Gaining Momentum
Why 89bio Stock Lagged the Market Today
89bio (ETNB 0.11%) couldn't quite keep pace with the broader stock market on Tuesday. Investors were hesitant to buy shares of the clinical-stage biotech, following news that it was floating a new stock issue.
89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward
89bio, Inc. results from the phase 3 ENTRUST study using pegozafermin for the treatment of patients with Severe Hypertriglyceridemia are expected in the 2nd half of 2025. Prior data from the phase 2 ENTRIGUE study indicated that patients treated with all doses of pegozafermin were able to achieve the primary endpoint with statistical significance. The global severe hypertriglyceridemia treatment market is expected to reach $2.67 billion by 2033.
